Phaseline

Companies › Molecure

Molecure: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OATD-01
Chitinase-1 (CHIT1) inhibitor
CHIT1Phase 2Pulmonary SarcoidosisAug 2027
OATD-02
Arginosuccinate synthetase 1 (ASS1) restoration or arginine level enhancement
–Phase 1Advanced Ovarian CarcinomaMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05759923OATD-02Phase 1Advanced Ovarian CarcinomaOncologyMar 2027
NCT06205121OATD-01Phase 2Pulmonary SarcoidosisImmunologyAug 2027

Targets

CHIT1 (1)

Companies with the same targets

–

Companies built like this

Telios Pharma Tavotek Biotherapeutics Xizang Haisco Pharmaceutical Ganzhou Hemay Pharmaceutical Antengene Biologics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.